FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175164501> ?p ?o ?g. }

• W3175164501 abstract "Improved assays are critical to the successful implementation of novel HIV-1 cure strategies, given the limited ability of currently available assays to quantify true effects on the viral reservoir. As interventions based on immune clearance target infected cells producing viral antigens, irrespective of whether the viruses generated are infectious or not, we developed a novel assay to identify viral protein production at the single-cell level. The novel viral protein spot (VIP-SPOT) assay, based on the enzyme-linked ImmunoSpot (ELISpot) approach, quantifies the frequency of CD4+ T cells that produce HIV antigen upon stimulation. The performance of the VIP-SPOT assay was validated in samples from viremic (n = 18) and antiretroviral therapy (ART)-treated subjects (n = 35), and the results were compared with total and intact proviral DNA and plasma viremia. The size of the functional reservoir, measured by VIP-SPOT, correlates with total HIV-1 DNA and, more strongly, with intact proviruses. However, the frequency of HIV antigen-producing cells is 100-fold lower than that of intact proviruses, thus suggesting that most latently infected cells harboring full-length proviruses are not prone to reactivation. Furthermore, VIP-SPOT was useful for evaluating the efficacy of latency reversing agents (LRAs) in primary cells. VIP-SPOT is a novel tool for measuring the size of the functional HIV-1 reservoir in a rapid, sensitive, and precise manner. It might benefit the evaluation of cure strategies based on immune clearance, as these will specifically target this minor fraction of the viral reservoir, and might assist in the identification of novel therapeutic candidates that modulate viral latency. IMPORTANCE Current efforts aimed at finding a definitive cure for HIV-1 infection are hampered mainly by the persistence of a viral reservoir in latently infected cells. While complete viral eradication from the body remains elusive, finding a functional cure to enable control of viremia without the need for continuous treatment is a key goal. As the lower reservoir size increases the likelihood of controlling viremia, new therapeutic strategies aim to reduce the size of this viral reservoir. Evaluating the efficacy of these strategies requires a robust assay to measure the viral reservoir. Currently available options are subject to overestimation or underestimation of the productive reservoir. In order to overcome this limitation, we have developed a novel assay, viral protein spot (VIP-SPOT), to precisely quantify the frequency of infected cells that retain the ability to reactivate and produce viral proteins." @default.
• W3175164501 created "2021-07-05" @default.
• W3175164501 creator A5017638207 @default.
• W3175164501 creator A5028130303 @default.
• W3175164501 creator A5028839627 @default.
• W3175164501 creator A5029224092 @default.
• W3175164501 creator A5037114070 @default.
• W3175164501 creator A5049177291 @default.
• W3175164501 creator A5056187765 @default.
• W3175164501 creator A5061338963 @default.
• W3175164501 creator A5072535578 @default.
• W3175164501 creator A5080494777 @default.
• W3175164501 creator A5087884352 @default.
• W3175164501 date "2021-06-29" @default.
• W3175164501 modified "2023-10-14" @default.
• W3175164501 title "VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies" @default.
• W3175164501 cites W1659719610 @default.
• W3175164501 cites W1964173449 @default.
• W3175164501 cites W1969872000 @default.
• W3175164501 cites W2030844138 @default.
• W3175164501 cites W2040695012 @default.
• W3175164501 cites W2063628696 @default.
• W3175164501 cites W2115580899 @default.
• W3175164501 cites W2117633297 @default.
• W3175164501 cites W2148999462 @default.
• W3175164501 cites W2335155851 @default.
• W3175164501 cites W2512878063 @default.
• W3175164501 cites W2517626897 @default.
• W3175164501 cites W2574522581 @default.
• W3175164501 cites W2605461991 @default.
• W3175164501 cites W2607272905 @default.
• W3175164501 cites W2609863249 @default.
• W3175164501 cites W2749571720 @default.
• W3175164501 cites W2784540562 @default.
• W3175164501 cites W2789029405 @default.
• W3175164501 cites W2795013247 @default.
• W3175164501 cites W2796259010 @default.
• W3175164501 cites W2901483227 @default.
• W3175164501 cites W2911228036 @default.
• W3175164501 cites W2916314751 @default.
• W3175164501 cites W2964709937 @default.
• W3175164501 cites W2996275436 @default.
• W3175164501 cites W3003221987 @default.
• W3175164501 cites W3005267901 @default.
• W3175164501 cites W3006385260 @default.
• W3175164501 cites W3012311927 @default.
• W3175164501 cites W3036355166 @default.
• W3175164501 cites W3047923714 @default.
• W3175164501 cites W3083359640 @default.
• W3175164501 cites W3114403040 @default.
• W3175164501 cites W3118306668 @default.
• W3175164501 doi "https://doi.org/10.1128/mbio.00560-21" @default.
• W3175164501 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8262951" @default.
• W3175164501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34154408" @default.
• W3175164501 hasPublicationYear "2021" @default.
• W3175164501 type Work @default.
• W3175164501 sameAs 3175164501 @default.
• W3175164501 citedByCount "7" @default.
• W3175164501 countsByYear W31751645012022 @default.
• W3175164501 countsByYear W31751645012023 @default.
• W3175164501 crossrefType "journal-article" @default.
• W3175164501 hasAuthorship W3175164501A5017638207 @default.
• W3175164501 hasAuthorship W3175164501A5028130303 @default.
• W3175164501 hasAuthorship W3175164501A5028839627 @default.
• W3175164501 hasAuthorship W3175164501A5029224092 @default.
• W3175164501 hasAuthorship W3175164501A5037114070 @default.
• W3175164501 hasAuthorship W3175164501A5049177291 @default.
• W3175164501 hasAuthorship W3175164501A5056187765 @default.
• W3175164501 hasAuthorship W3175164501A5061338963 @default.
• W3175164501 hasAuthorship W3175164501A5072535578 @default.
• W3175164501 hasAuthorship W3175164501A5080494777 @default.
• W3175164501 hasAuthorship W3175164501A5087884352 @default.
• W3175164501 hasBestOaLocation W31751645013 @default.
• W3175164501 hasConcept C147483822 @default.
• W3175164501 hasConcept C159047783 @default.
• W3175164501 hasConcept C203014093 @default.
• W3175164501 hasConcept C2776090121 @default.
• W3175164501 hasConcept C2776185481 @default.
• W3175164501 hasConcept C2779053233 @default.
• W3175164501 hasConcept C3013748606 @default.
• W3175164501 hasConcept C71924100 @default.
• W3175164501 hasConcept C86803240 @default.
• W3175164501 hasConcept C8891405 @default.
• W3175164501 hasConceptScore W3175164501C147483822 @default.
• W3175164501 hasConceptScore W3175164501C159047783 @default.
• W3175164501 hasConceptScore W3175164501C203014093 @default.
• W3175164501 hasConceptScore W3175164501C2776090121 @default.
• W3175164501 hasConceptScore W3175164501C2776185481 @default.
• W3175164501 hasConceptScore W3175164501C2779053233 @default.
• W3175164501 hasConceptScore W3175164501C3013748606 @default.
• W3175164501 hasConceptScore W3175164501C71924100 @default.
• W3175164501 hasConceptScore W3175164501C86803240 @default.
• W3175164501 hasConceptScore W3175164501C8891405 @default.
• W3175164501 hasFunder F4320308573 @default.
• W3175164501 hasFunder F4320328449 @default.
• W3175164501 hasIssue "3" @default.
• W3175164501 hasLocation W31751645011 @default.
• W3175164501 hasLocation W31751645012 @default.
• W3175164501 hasLocation W31751645013 @default.
• W3175164501 hasLocation W31751645014 @default.

• next